Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciafaloni, E.
Right arrow Articles by Sanders, D.B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciafaloni, E.
Right arrow Articles by Sanders, D.B.
Related Collections
Right arrow Myasthenia
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)

Mycophenolate mofetil for myasthenia gravis: An open-label pilot study

E. Ciafaloni, MD;, J.M. Massey, MD;, B. Tucker–Lipscomb, RN, BSN, APN; and D.B. Sanders, MD

From the Division of Neurology, Duke University Medical Center, Durham, NC.



View larger version (24K):

[in a new window]
  		Figure. Manual muscle testing. Score each function as: 0 = normal; 1 = 25% weak/mild impairment; 2 = 50% weak/moderate impairment; 3 = 75% weak/severe impairment; 4 = paralyzed/unable to do.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.